Drug intelligence / Profile preview

CORT-002

Development stage: Preclinical
Lead developer: Xeris Biopharma
Modality: Small Molecules

Overview

CORT-002 is an investigational small molecule drug candidate originally developed by Cortendo for the treatment of microvascular angina. Following the acquisition of Cortendo by Strongbridge Biopharma and the subsequent acquisition of Strongbridge by Xeris Pharmaceuticals, the program's status remains in the early discovery or preclinical stages. While it is categorized within the therapeutic areas of cardiovascular and nervous system diseases, its specific molecular targets and mechanism of action have not been publicly disclosed.

Beyond the preview

Go deeper on CORT-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CORT-002.

Explore the full profile